Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...
The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with ...
Pfizer announced it has entered into an exclusive global collaboration and license agreement with Chongqing Yao ...
Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, ...
OTR Therapeutics Announces Collaboration with Zealand Pharma to Develop Metabolic Disease Treatments
OTR Therapeutics and Zealand Pharma collaborate to develop novel metabolic disease treatments, with a potential deal value of ...
PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of ...
PE: How will recent regulatory developments at FDA impact feasibility assessments in clinical planning? Woollett: It’s ...
Fondazione Telethon announced that FDA has approved its Biologics License Application (BLA) for Waskyra (etuvetidigene ...
DTC prescription drug models are reshaping the pharma industry by altering pricing dynamics and enhancing patient access, ...
For Phase III trial planning, two suggestions may have merit. Include sizeable subpopulations that payers cannot easily ...
In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the ...
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback